USE OF BETA-ADRENOBLOCKERS IN THE TREATMENT OF ARTERIAL HYPERTENSION IN PREGNANT WOMEN


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The fact that the fetal safety of antihypertensive agents has been little studied limits their choice to treat arterial hypertension in pregnant women. In the Russian Federation, this problem is more acute than in other countries of Europe and the United States because labetalol is commercially unavailable. The results of small clinical trials that have indicated the efficacy and no negative effects of the highly selective metabolically neutral beta-blocker bisoprolol show that it is promising to further investigate its gestational safety in retrospective and prospective studies.

Full Text

Restricted Access

About the authors

N. K RUNIKHINA

Academician V.I. Kulakov Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health and Social Development of Russia

Email: runishi@rambler.ru

E. A USHKALOVA

Academician V.I. Kulakov Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health and Social Development of Russia

Email: eushk@yandex.ru

References

  1. Барабашкина А.В., Верткин А.Л., Ткачева О.Н., Кирюхин А.В., Семенова Л.Л., Васильева А.В. Применение небиволола для лечения артериальной гипертонии в период беременности. Российский кардиологический журнал. 2005; 3: 47-52.
  2. Барабашкина А.В., Ткачева О.Н., Васильева А.В., Разгуляева Н.Ф. Перспективы оптимизации фармакотерапии артериальной гипертонии в период беременности. Российский кардиологический журнал. 2006; 4: 75-82.
  3. Брыткова Я.В., Игнатьев И.В., Казаков Р.Е., Сокова Е.А., Стрюк Р.И. Эффективность и безопасность бисопролола у беременных с хронической артериальной гипертонией не зависят от генетического полиморфизма гена CYP2D6. Кардиология. 2009; 49(7-8): 50-5.
  4. Верткин А.Л., Ткачева О.Н., Мурашко Л. Е., Мишина И.Е., Тумбаев И.В. Артериальная гипертония беременных: диагностика, тактика ведения и подходы к лечению. Российский кардиологический журнал. 2003; 6: 59-65.
  5. Манухин И.Б., Маркова Е.В., Маркова Л.И., Стрюк Р.И. Комбинированная низкодозовая антигипертензивная терапия у беременных с артериальной гипертонией и гестозом. Кардиология. 2012; 52(1): 32-8.
  6. Осадчий К.К. p-Адреноблокаторы при артериальной гипертензии: фокус на бисопролол. Кардиология. 2010; 50(1): 84-9.
  7. Стрюк Р.И., Брыткова Я.В., Бухонкина Ю.М., Павлова Л.Н. Клиническая эффективность антигипер-тензивной терапии пролонгированным нифедипином и бисопрололом беременных с артериальной гипертонией. Кардиология. 2008; 48(4): 29-33.
  8. Стрюк Р.И., Бухонкина Ю.М., Смирнова В.А., Чижова Г.В. Функция эндотелия и маточно-плодово-плацентарный кровоток у беременных с артериальной гипертонией. Кардиология. 2010; 50(4): 18-22.
  9. Ткачева О.Н., Рунихина Н.К., Чухарева Н.А., Шарашкина Н.В. Спорные вопросы артериальной гипертензии в период беременности. Фарматека. 2012; 4 (237): 20-6.
  10. Фролов А.В., Сычев О.С., Пелех Н.В. Применение бета-блокаторов для лечения нарушений ритма сердца у беременных при длительном наблюдении. Мистецтво лжування. 2006; 3: 70-3.
  11. Шилов А.М. Бисопролол - кардиоселективный бета-блокатор второго поколения в практике лечения артериальной гипертонии. Фарматека. 2006; 8(123): 65-71.
  12. Abalos E., Duley L., Steyn D.W., Henderson-Smart D.J. Antihypertensive drug therapy for mild to moderate hypertension during pregnancy. Cochrane Database Syst. Rev. 2007; (1): CD002252.
  13. Aronow W.S. Current role of beta-blockers in the treatment of hypertension. Expert Opin. Pharmacother. 2010; 11(16): 2599-607.
  14. Aursnes I., Osnes J.B., Tvete I.F., Gasemyr J., Natvig B. Does atenolol differ from other B-adrenergic blocker? BMC Clin. Pharmacol. 2007;7:4.
  15. Boutroy M.J., Morsell P.L.,Bianchetti G.,Boutroy J.L.,Pepin L., Zipfel A. Betaxolol: a pilot study of its pharmacological and therapeutic properties in pregnancy. Eur. J. Clin. Pharmacol. 1990; 38(6): 535-9.
  16. Briggs G.G., Freeman R.K., Yaffe S.J. Drugs in pregnacy and lactation: a reference guide to fetal and neonatal risk. 7-th ed. Philadelphia: Lippincott Williams&Wilkins; 2005. 1858 p.
  17. Carr D.B., Tran L.T., BratengD.A., Kawamura C., Shofer J.B., Karumanchi S.A., Easterling T.R. Hemodynamically-directed atenolol therapy is associated with a blunted rise in maternal sFLT-1 levels during pregnancy. Hypertens. Pregnancy. 2009; 28(1): 42-55.
  18. Cifkova R. Why is the treatment of hypertension in pregnancy still so difficult? Expert Rev. Cardiovasc. Ther. 2011; 9(6): 647-9.
  19. Dubois D., Petitcolas J., Temperville B., Klepper A., Catherine P.H. Treatment of hypertension in pregnancy with b-adrenoceptor antagonists. Br. J. Clin. Pharmacol. 1982; 13(suppl.): 375S-8S.
  20. Easterling T.R., Brateng D., Schmucker B., Brown Z, Millard S.P. Prevention of preeclampsia: a randomized trial of atenolol in hyperdynamic patients before onset of hypertension. Obstet. Gynecol. 1999; 93(5, pt. 1): 725-33.
  21. Gerard J., Blazquez G., Lardoux H., Beausejour., Faurie C, Rousset D., Flouvat B. Effect of 2 beta-blockers on arterial hypertension during pregnancy. Results of a prospective study on 56 pregnant hypertensive women treated with atenolol and labetalol. J. Gynecol. Obstet. Biol. Reprod. (Paris). 1983; 12(8): 891—900.
  22. Goodlin R.C. Beta blocker in pregnancy-induced hypertension. Am. J. Obstet. Gynecol. 1982; 143(2): 237.
  23. Handler J. Managing chronic severe hypertension in pregnancy. J. Clin. Hypertens. (Greenwich). 2006; 8(10): 738-43.
  24. Hypertension in pregnancy: The management of hypertensive disorders during pregnancy. NICE Clinical Guidelines, No. 107. National Collaborating Centre for Women’s and Children’s Health (UK). London: RCOG Press; 2010: Aug.
  25. Lindheimer M.D., Taler S.J., Cunningham F.G. American Society of Hypertension. ASH position paper: hypertension in pregnancy. J. Clin. Hypertens. (Greenwich). 2009; 11(4): 214-25.
  26. Lunell N.O., Nylund L, Lewander R, Sarby B., Wager J. Uteroplacental blood flow in pregnancy hypertension after the administration of a beta-adrenoceptor blocker, pindolol. Gynecol. Obstet. Invest. 1984; 18: 269-74.
  27. Magee L.A., Helewa M.E., Moutquin J.M. et al. Diagnosis, evaluation, and management of the hypertensive disorders of pregnancy. This guideline has been reviewed and approved by the Hypertension Guideline Committee and approved by the Executive and Council of the Society of Obstetricians and Gynaecologists of Canada. J. Obstet.Gynecol. Can. 2008; 48.
  28. Magee L.A., Cham C, Waterman E.J., Ohlsson A., von Dadelszen P. Hydralazine for treatment of severe hypertension in pregnancy: meta-analysis. Br.Med. J. 2003; 327(7421): 955—60.
  29. Magee L.A., Duley L. Oral beta-blockers for mild to moderate hypertension during pregnancy. Cochrane Database Syst. Rev. 2003; (3): CD002863.
  30. Magee L.A., Elran E, Bull S.B., Logan A., Koren G. Risks and benefits of beta-receptor blockers for pregnancy hypertension: overview of the randomized trials. Eur. J. Obstet. Gynecol. Reprod. Biol. 2000;.88: 15-26.
  31. Mahmud H, Foller M., Lang F. Stimulation of erythrocyte cell membrane scrambling by methyldopa. Kidney Blood Press Res. 2008; 31(5): 299-306.
  32. Meidahl Petersen K, Jimenez-Solem E., Andersen J.T., Petersen M., Bndbxk K., K0ber L. et al. p-Blocker treatment during pregnancy and adverse pregnancy outcomes: a nationwide population-based cohort study. BMJ Open. 2012; 2(4): e001185.
  33. Meizner I., Paran E., Katz M., Holcberg G., Insler V. Flow velocity analysis of umbilical and uterine artery flow in pre-eclampsia treated with propranolol or pindolol. J. Clin. Ultrasound. 1992; 20: 1159.
  34. Mustafa R., Ahmed S., Gupta A., Venuto R.C. A comprehensive review of hypertension in pregnancy. J. Pregnancy. 2012; 2012:105918.
  35. Oumachigui A., Verghese M., Balachander J. A comparative evaluation of metoprolol and methyldopa in the management of pregnancy induced hypertension. Indian Heart J. 1992; 44(1): 39—41.
  36. Ozdemir O.M., Ergin H., Ince T. A newborn with positive antiglobulin test whose mother took methyldopa in pregnancy. Turk. J. Pediatr. 2008; 50(6): 592-4.
  37. Pickering T.G., Hall J.E., Appel L.J., Falkner B.E., Graves J., Hill M.N. et al. Recommendations for blood pressure measurement in humans. A statement for professionals from the Subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research. Hypertension. 2005; 45: 142-61.
  38. Pierce A., Nester T. Pathology consultation on drug-induced hemolytic anemia. Am. J. Clin. Pathol. 2011; 136(1): 7-12.
  39. Podymow T., August P. Update on the use of antihypertensive drugs in pregnancy. Hypertension. 2008; 51(4): 960-9.
  40. Reynolds B., Butters L., Evans J., Adams T., Rubin P.C. First year of life after the use of atenolol in pregnancy associated hypertension. Arch. Dis. Child. 1984; 59: 1061-3.
  41. Seremak-Mrozikiewicz A., Drews K. Methyldopa in therapy of hypertension in pregnant women. Ginekol. Pol. 2004; 75(2): 160-5.
  42. Soucek M., Prasek J., Spinarova L. Atenolol and bisoprolol in the treatment of mild and moderately severe hypertension. Vnitr. Lek. 1993; 39(6): 541-8.
  43. Tuimala R., Hartikainen-Sorri A.-L. Randomized comparison of atenolol and pindolol for treatment of hypertension in pregnancy. Curr. Ther. Res. 1988; 44: 579-84.
  44. Valensise H., Vasapollo B., Novelli G.P. et al. Maternal and fetal hemodynamic effects induced by nitric oxide donors and plasma volume expansion in pregnancies with gestational hypertension complicated by intrauterine growth restriction with absent end-diastolic flow in the umbilical artery. Ultrasound Obstet. Gynecol. 2008; 31(1): 55-64.
  45. Venuto R., Burstein P., Schneider R. Pheochromocytoma: antepartum diagnosis and management with tumor resection in the puerperium. Am. J. Obstet. Gynecol. 1984; 150(4): 431-2.
  46. von Dadelszen P., Ornstein M.P., Bull S.B., Logan A.G., Koren G., Magee L.A. Fall in mean arterial pressure and fetal growth restriction in pregnancy hypertension: a metaanalysis. Lancet. 2000; 355(9198): 87-92.
  47. Whitelaw A. Maternal methyldopa treatment and neonatal blood pressure. Br. Med. J. 1981; 283: 471.
  48. Zeitlin J., ElA M., Jarreau P.H., Draper E.S., Blondel B., Ktinzel W. et al. Impact of foetal growth restriction on mortality and morbidity in a very preterm birth cohort. J. Pediatr. 2010; 157: 733-9.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies